MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.
Identifieur interne : 000C25 ( Main/Exploration ); précédent : 000C24; suivant : 000C26MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.
Auteurs : Safi Alqatari [Oman] ; Peter Riddell [Irlande (pays)] ; Sinead Harney [Irlande (pays)] ; Michael Henry [Irlande (pays)] ; Grainne Murphy [Irlande (pays)]Source :
- BMC pulmonary medicine [ 1471-2466 ] ; 2018.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticorps anti-idiotypiques (sang), Cyclophosphamide (usage thérapeutique), Dermatomyosite (), Dermatomyosite (diagnostic), Dermatomyosite (traitement médicamenteux), Femelle, Humains, Hélicase IFIH1 inductrice de l'interféron (métabolisme), Issue fatale, Pneumopathies interstitielles (diagnostic), Pneumopathies interstitielles (traitement médicamenteux), Pneumothorax (), Rituximab (usage thérapeutique), Tomodensitométrie, Évolution de la maladie.
- MESH :
- diagnostic : Dermatomyosite, Pneumopathies interstitielles.
- métabolisme : Hélicase IFIH1 inductrice de l'interféron.
- sang : Anticorps anti-idiotypiques.
- traitement médicamenteux : Dermatomyosite, Pneumopathies interstitielles.
- usage thérapeutique : Cyclophosphamide, Rituximab.
- Adulte d'âge moyen, Dermatomyosite, Femelle, Humains, Issue fatale, Pneumothorax, Tomodensitométrie, Évolution de la maladie.
English descriptors
- KwdEn :
- Antibodies, Anti-Idiotypic (blood), Cyclophosphamide (therapeutic use), Dermatomyositis (complications), Dermatomyositis (diagnosis), Dermatomyositis (drug therapy), Disease Progression, Fatal Outcome, Female, Humans, Interferon-Induced Helicase, IFIH1 (metabolism), Lung Diseases, Interstitial (diagnosis), Lung Diseases, Interstitial (drug therapy), Middle Aged, Pneumothorax (complications), Rituximab (therapeutic use), Tomography, X-Ray Computed.
- MESH :
- chemical , blood : Antibodies, Anti-Idiotypic.
- chemical , metabolism : Interferon-Induced Helicase, IFIH1.
- chemical , therapeutic use : Cyclophosphamide, Rituximab.
- complications : Dermatomyositis, Pneumothorax.
- diagnosis : Dermatomyositis, Lung Diseases, Interstitial.
- drug therapy : Dermatomyositis, Lung Diseases, Interstitial.
- Disease Progression, Fatal Outcome, Female, Humans, Middle Aged, Tomography, X-Ray Computed.
Abstract
Clinically hypomyopathic dermatomyositis is a rare disease that is important to recognize, investigate and treat early as it is associated with poor prognosis. In a proportion of patients, myositis specific antibodies could be negative, but with high clinical suspicion, myositis associated antibodies should be ordered. Anti-MDA-5 antibodies was reported in literature to be associated with severe and rapidly progressive interstitial lung disease, with few case reports of pneumothorax and/or pneumomediastinum.
DOI: 10.1186/s12890-018-0622-8
PubMed: 29665800
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000114
- to stream PubMed, to step Curation: 000114
- to stream PubMed, to step Checkpoint: 000098
- to stream Ncbi, to step Merge: 000439
- to stream Ncbi, to step Curation: 000439
- to stream Ncbi, to step Checkpoint: 000439
- to stream Main, to step Merge: 000C25
- to stream Main, to step Curation: 000C25
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.</title><author><name sortKey="Alqatari, Safi" sort="Alqatari, Safi" uniqKey="Alqatari S" first="Safi" last="Alqatari">Safi Alqatari</name><affiliation wicri:level="1"><nlm:affiliation>Royal College of Physicians of Ireland, Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland, T12 DC4A. alqatarisafi@hotmail.com.</nlm:affiliation><country wicri:rule="url">Oman</country></affiliation></author><author><name sortKey="Riddell, Peter" sort="Riddell, Peter" uniqKey="Riddell P" first="Peter" last="Riddell">Peter Riddell</name><affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author><author><name sortKey="Harney, Sinead" sort="Harney, Sinead" uniqKey="Harney S" first="Sinead" last="Harney">Sinead Harney</name><affiliation wicri:level="1"><nlm:affiliation>Internal Medicine and Rheumatology Consultant Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Internal Medicine and Rheumatology Consultant Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author><author><name sortKey="Henry, Michael" sort="Henry, Michael" uniqKey="Henry M" first="Michael" last="Henry">Michael Henry</name><affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author><author><name sortKey="Murphy, Grainne" sort="Murphy, Grainne" uniqKey="Murphy G" first="Grainne" last="Murphy">Grainne Murphy</name><affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29665800</idno><idno type="pmid">29665800</idno><idno type="doi">10.1186/s12890-018-0622-8</idno><idno type="wicri:Area/PubMed/Corpus">000114</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000114</idno><idno type="wicri:Area/PubMed/Curation">000114</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000114</idno><idno type="wicri:Area/PubMed/Checkpoint">000098</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000098</idno><idno type="wicri:Area/Ncbi/Merge">000439</idno><idno type="wicri:Area/Ncbi/Curation">000439</idno><idno type="wicri:Area/Ncbi/Checkpoint">000439</idno><idno type="wicri:Area/Main/Merge">000C25</idno><idno type="wicri:Area/Main/Curation">000C25</idno><idno type="wicri:Area/Main/Exploration">000C25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.</title><author><name sortKey="Alqatari, Safi" sort="Alqatari, Safi" uniqKey="Alqatari S" first="Safi" last="Alqatari">Safi Alqatari</name><affiliation wicri:level="1"><nlm:affiliation>Royal College of Physicians of Ireland, Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland, T12 DC4A. alqatarisafi@hotmail.com.</nlm:affiliation><country wicri:rule="url">Oman</country></affiliation></author><author><name sortKey="Riddell, Peter" sort="Riddell, Peter" uniqKey="Riddell P" first="Peter" last="Riddell">Peter Riddell</name><affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author><author><name sortKey="Harney, Sinead" sort="Harney, Sinead" uniqKey="Harney S" first="Sinead" last="Harney">Sinead Harney</name><affiliation wicri:level="1"><nlm:affiliation>Internal Medicine and Rheumatology Consultant Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Internal Medicine and Rheumatology Consultant Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author><author><name sortKey="Henry, Michael" sort="Henry, Michael" uniqKey="Henry M" first="Michael" last="Henry">Michael Henry</name><affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author><author><name sortKey="Murphy, Grainne" sort="Murphy, Grainne" uniqKey="Murphy G" first="Grainne" last="Murphy">Grainne Murphy</name><affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, Cork University Hospital, Wilton, Cork, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Rheumatology Department, Cork University Hospital, Wilton, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation></author></analytic><series><title level="j">BMC pulmonary medicine</title><idno type="eISSN">1471-2466</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Anti-Idiotypic (blood)</term><term>Cyclophosphamide (therapeutic use)</term><term>Dermatomyositis (complications)</term><term>Dermatomyositis (diagnosis)</term><term>Dermatomyositis (drug therapy)</term><term>Disease Progression</term><term>Fatal Outcome</term><term>Female</term><term>Humans</term><term>Interferon-Induced Helicase, IFIH1 (metabolism)</term><term>Lung Diseases, Interstitial (diagnosis)</term><term>Lung Diseases, Interstitial (drug therapy)</term><term>Middle Aged</term><term>Pneumothorax (complications)</term><term>Rituximab (therapeutic use)</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps anti-idiotypiques (sang)</term><term>Cyclophosphamide (usage thérapeutique)</term><term>Dermatomyosite ()</term><term>Dermatomyosite (diagnostic)</term><term>Dermatomyosite (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Hélicase IFIH1 inductrice de l'interféron (métabolisme)</term><term>Issue fatale</term><term>Pneumopathies interstitielles (diagnostic)</term><term>Pneumopathies interstitielles (traitement médicamenteux)</term><term>Pneumothorax ()</term><term>Rituximab (usage thérapeutique)</term><term>Tomodensitométrie</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Anti-Idiotypic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interferon-Induced Helicase, IFIH1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cyclophosphamide</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dermatomyositis</term><term>Pneumothorax</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dermatomyositis</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Dermatomyosite</term><term>Pneumopathies interstitielles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dermatomyositis</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hélicase IFIH1 inductrice de l'interféron</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps anti-idiotypiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dermatomyosite</term><term>Pneumopathies interstitielles</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cyclophosphamide</term><term>Rituximab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Fatal Outcome</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Dermatomyosite</term><term>Femelle</term><term>Humains</term><term>Issue fatale</term><term>Pneumothorax</term><term>Tomodensitométrie</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clinically hypomyopathic dermatomyositis is a rare disease that is important to recognize, investigate and treat early as it is associated with poor prognosis. In a proportion of patients, myositis specific antibodies could be negative, but with high clinical suspicion, myositis associated antibodies should be ordered. Anti-MDA-5 antibodies was reported in literature to be associated with severe and rapidly progressive interstitial lung disease, with few case reports of pneumothorax and/or pneumomediastinum.</div></front></TEI><affiliations><list><country><li>Irlande (pays)</li><li>Oman</li></country></list><tree><country name="Oman"><noRegion><name sortKey="Alqatari, Safi" sort="Alqatari, Safi" uniqKey="Alqatari S" first="Safi" last="Alqatari">Safi Alqatari</name></noRegion></country><country name="Irlande (pays)"><noRegion><name sortKey="Riddell, Peter" sort="Riddell, Peter" uniqKey="Riddell P" first="Peter" last="Riddell">Peter Riddell</name></noRegion><name sortKey="Harney, Sinead" sort="Harney, Sinead" uniqKey="Harney S" first="Sinead" last="Harney">Sinead Harney</name><name sortKey="Henry, Michael" sort="Henry, Michael" uniqKey="Henry M" first="Michael" last="Henry">Michael Henry</name><name sortKey="Murphy, Grainne" sort="Murphy, Grainne" uniqKey="Murphy G" first="Grainne" last="Murphy">Grainne Murphy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29665800
|texte= MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29665800" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |